These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 26315567)

  • 21. The XprESS Multi-Sinus Dilation System for the Treatment of Chronic Sinusitis: A NICE Medical Technology Guidance.
    Jenks M; Willits I; Turner EE; Hewitt N; Arber M; Cole H; Craig J; Sims A
    Appl Health Econ Health Policy; 2017 Oct; 15(5):567-582. PubMed ID: 28669043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Morgan P; Woolacott N; Biswas M; Mebrahtu T; Harden M; Hodgson R
    Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Grimm SE; Witlox W; Wolff R; Chalker A; Hiligsmann M; Wijnen B; Ahmadu C; Ryder S; Armstrong N; Duffy S; Syndikus I; Kleijnen J; Joore MA
    Pharmacoeconomics; 2022 May; 40(5):509-518. PubMed ID: 34664200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence.
    Llewellyn A; Faria R; Woods B; Simmonds M; Lomas J; Woolacott N; Griffin S
    Pharmacoeconomics; 2016 Oct; 34(10):981-92. PubMed ID: 27278217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal.
    Rodgers M; Griffin S; Paulden M; Slack R; Duffy S; Ingram JR; Woolacott N; Sculpher M
    Pharmacoeconomics; 2010; 28(5):351-62. PubMed ID: 20131924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Ren S; Simpson E; Clowes M; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Dec; 36(12):1427-1437. PubMed ID: 29882210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Stevenson M; Pandor A; Hamilton J; Stevens J; Rowntree C; Martyn-St James M; Rawdin A; Wong R
    Pharmacoeconomics; 2018 Jul; 36(7):759-768. PubMed ID: 29502175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ren S; Bermejo I; Simpson E; Wong R; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Jul; 36(7):769-778. PubMed ID: 29502174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ibrutinib for Treating Waldenström's Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P; Carroll C; Stevens J; Simpson E; Thokala P; Wong R; Wright J; Auer R
    Pharmacoeconomics; 2019 Jan; 37(1):7-18. PubMed ID: 29951793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence.
    Wade R; Hodgson R; Biswas M; Harden M; Woolacott N
    Pharmacoeconomics; 2017 Feb; 35(2):203-213. PubMed ID: 27592020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review of Economic Submissions to NICE Medical Technologies Evaluation Programme.
    Alshreef A; Jenks M; Green W; Dixon S
    Appl Health Econ Health Policy; 2016 Dec; 14(6):623-634. PubMed ID: 27480537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ponatinib for Treating Chronic Myeloid Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Pandor A; Stevenson M; Stevens J; James MM; Hamilton J; Byrne J; Rudin C; Rawdin A; Wong R
    Pharmacoeconomics; 2018 Aug; 36(8):903-915. PubMed ID: 29480454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence.
    Lomas J; Llewellyn A; Soares M; Simmonds M; Wright K; Eastwood A; Palmer S
    Pharmacoeconomics; 2016 Sep; 34(9):901-12. PubMed ID: 27289476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Stevenson M; Archer R; Stevens JW; Goka E; Clowes M; Scott DL; Young A
    Pharmacoeconomics; 2017 Nov; 35(11):1141-1151. PubMed ID: 28550592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PleurX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites: a NICE Medical Technology Guidance.
    White J; Carolan-Rees G
    Appl Health Econ Health Policy; 2012 Sep; 10(5):299-308. PubMed ID: 22779402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virtual Touch™ Quantification to Diagnose and Monitor Liver Fibrosis in Hepatitis B and Hepatitis C: A NICE Medical Technology Guidance.
    Summers JA; Radhakrishnan M; Morris E; Chalkidou A; Rua T; Patel A; McMillan V; Douiri A; Wang Y; Ayis S; Higgins J; Keevil S; Lewis C; Peacock J
    Appl Health Econ Health Policy; 2017 Apr; 15(2):139-154. PubMed ID: 27601240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Al Khayat MNMT; Armstrong N; Howick J; O'Meara S; Posadzki P; Ryder S; Ahmadu C; Konings SRA; Postma MJ; Duffy S; Wolff RF; van Asselt ADI
    Pharmacoeconomics; 2023 Apr; 41(4):353-361. PubMed ID: 36757608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Büyükkaramikli NC; de Groot S; Riemsma R; Fayter D; Armstrong N; Portegijs P; Duffy S; Kleijnen J; Al MJ
    Pharmacoeconomics; 2019 Feb; 37(2):141-153. PubMed ID: 30194622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Grimm SE; Wijnen B; Riemsma R; Fayter D; Armstrong N; Ahmadu C; Brandts L; Misso K; Kirwan JR; Kleijnen J; Joore MA
    Pharmacoeconomics; 2021 Dec; 39(12):1397-1410. PubMed ID: 34448148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
    Rose M; Shepherd J; Harris P; Pickett K; Lord J
    Pharmacoeconomics; 2018 Nov; 36(11):1299-1308. PubMed ID: 29691773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.